Immunoconjugates: Current status and future potential

Journal of Drug Targeting

Volumn 10, Issue 7, 2002, Pages 525-527

  Eaton, Mike ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Chimeric antibodies; Immunoconjugates; Immunogenicity; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; CALICHEAMICIN; CD33 ANTIGEN; DIMER; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN F(AB) FRAGMENT; LIPOSOME; PLASMID DNA; PRODRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; BIOTECHNOLOGY; CHIMERA; CLINICAL STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EDITORIAL; GENE THERAPY; HUMAN; IMMUNOGENICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY;

DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; HUMANS; IMMUNOCONJUGATES; TOXINS, BIOLOGICAL;

EID: 0036875067     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1061186021000038067     Document Type: Editorial

References (6)

1. Garnett, M.C. (2002) "Targeted drug conjugates: principles and progress", Advanced Drug Delivery Reviews 53, 171-216.
2. Hamann, P.R., Hinman, L.M., Hollander, I., Beyer, C.F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H-R., Upeslacis, J. and Shochat, D. (2002a) "Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia", Bioconjugate Chemistry 13(1), 47-58.
3. Hamann, P.R., Hinman, L.M., Beyer, C.F., Lindh, D., Upeslacis, J., Flowers, D.A. and Bernstein, I. (2002b) "An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker", Bioconjugate Chemistry 13(1), 40-46.
4. Jung, M. (2001) "Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy", Mini-Reviews in Medicinal Chemistry 1(4), 399-407.
5. Sievers, E.L. and Linenberger, M. (2001) "Mylotarg: antibody-targeted chemotherapy comes of age", Current Opinion in Oncology 13(6), 522-527.
6. Wiseman, G.A., Leigh, B., Erwin, W.D., Dominick, L., Kornmehl, E., Spies, S.M., Silverman, D.H.S., Witzig, T.E., Sparks, R.B. and White, C.A. (2002) "Radiation dosimetry results for zevalin radioimmuno-therapy of rituximab-refractory non-Hodgkin lymphoma", Cancer 94(Suppl. 4), 1349-1357.